Alle Storys
Folgen
Keine Story von Stada Arzneimittel mehr verpassen.

Stada Arzneimittel

Press release: NTC and STADA partner for a portfolio of ophthalmic products in the MENA region

Ein Dokument

NTC and STADA partner for a portfolio of ophthalmic products in the MENA region

  • NTC is granting to STADA license and distribution rights for certain proprietary ophthalmic products in the MENA region
  • The licensed products are intended to address several ophthalmic diseases, in particular blepharitis, dry eye and allergy
  • Carsten Cron, STADA’s Head of Emerging Markets: “By combining NTC’s ophthalmology expertise with STADA’s deep sales and marketing footprint in the MENA region, we look forward to offering patients and healthcare professionals an attractive range of options for care for eye health.”

7 September 2021 – NTC, an international pharmaceutical company headquartered in Milan, Italy, and STADA, a global leading pharmaceutical player with significant presence in the Middle East and North Africa (MENA) region, today announce a commercial ophthalmic partnership. NTC is granting to STADA license and distribution rights for certain proprietary ophthalmic products in the region, intended to address several ophthalmic diseases, in particular blepharitis, dry eye and allergy.

“We are excited to partner with a leading company like STADA,” – says Riccardo Carbucicchio, President and CEO of NTC – “for some of our innovative treatments in ophthalmology. The products included in the agreement with STADA leverage technologies aimed at simplifying the therapeutic care of patients in treating dry eye, allergy, and blepharitis, and thus favoring compliance. An agreement with a global player like STADA is a great opportunity for our vision at NTC and we are confident that our ophthalmic products will reach a broad range of patients in the MENA region.”

“By combining NTC’s ophthalmology expertise with STADA’s deep sales and marketing footprint in the MENA region, we look forward to offering patients and healthcare professionals an attractive range of options for care for eye health,” commented Carsten Cron, STADA’s Head of Emerging Markets. “The ophthalmic products will further strengthen STADA’s Specialty pipeline in the region that was recently reinforced through partnerships for oncology, allergy and anaesthetic medicines.”

NTC is running a large international research and development program in ophthalmology, engaging many researchers and clinical centers, focusing on developing novel therapeutic solutions to offer relief for still unmet needs to the medical community and the patients.

NTC information for journalists:

NTC Srl,   M. Claudia Nacci
Corporate Communication
mob: +39 349 0592805
E-mail: claudia.nacci@ntcpharma.com
Or visit us at  www.ntcpharma.com

STADA information for journalists:

STADA Arzneimittel AG - Media Relations
 Stadastrasse 2-18
 61118 Bad Vilbel - Germany 
Phone: +49 (0) 6101 603-165
 Fax: +49 (0) 6101 603-215
E-Mail:  press@stada.de 

Or visit us on the Internet at www.stada.com/press

Follow @STADAGroup on LinkedIn
 

STADA information for capital market participants:

STADA Arzneimittel AG - Investor & Creditor Relations
 Stadastrasse 2-18
 61118 Bad Vilbel – Germany
 Phone: +49 (0) 6101 603-4689
 Fax: +49 (0) 6101 603-215
E-mail:  ir@stada.de 

Or visit us on the Internet at www.stada.com/investor-relations

Weitere Storys: Stada Arzneimittel
Weitere Storys: Stada Arzneimittel